875 terminated. 875 Phase 2, 260 Phase 1, 15 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 875 | Terminated 875 |
| Phase 1 | 260 | Terminated 260 |
| Phase 3 | 15 | Terminated 15 |
Follow Lymphoproliferative Disorders: new trials by email Literature Review of Lymphoproliferative Disorders trials Research Report on Lymphoproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 4SCAR-CD44v6 T Cell Therapy Targeting Cancer CD44v6-specific CAR gene-engineered T cells - Cancers Which Are CD44v6 Positive | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2026-06-01 | 2026-08-24 |
| Combination CAR-T Cell Therapy Targeting Hematological Malignancies 4SCAR19 and 4SCAR22, 4SCAR19 and 4SCAR38, 4SCAR19 and 4SCAR20 - B-cell Malignancies | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2025-08-01 | 2026-08-24 |
| Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma IPH6501 - Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Innate Pharma | 23 | 2024-03-04 | 2026-04-14 |
| Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma Apheresis, Autologous Stem Cell Transplantation, CAR-T Cell Therapy - Lymphoma, B-Cell, Autologous Stem Cell Transplantation | Phase 2 | Terminated | The First Affiliated Hospital of Soochow University | 8 | 2024-01-01 | 2026-06-05 |
| A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma Forimtamig, Carfilzomib, Daratumumab - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 21 | 2023-12-08 | 2026-09-29 |
| Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy ALLO-647, Fludarabine, Cyclophosphamide - Relapsed/Refractory Large B Cell Lymphoma | Phase 2 | Terminated | Allogene Therapeutics | 2 | 2023-11-01 | 2026-03-02 |
| Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL AFM13, AB-101, Cyclophosphamide - Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma | Phase 2 | Terminated | Affimed GmbH | 25 | 2023-10-10 | 2025-08-20 |
| TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) 400mg of TQB3909 tablets, 600mg of TQB3909 tablets - Mantle Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 19 | 2023-10-05 | 2025-12-30 |
| A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma GEN3017 - Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Genmab | 9 | 2023-09-21 | 2025-09-25 |
| A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. maplirpacept (PF-07901801), Glofitamab, Obinutuzumab - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Pfizer | 40 | 2023-08-30 | 2026-05-06 |
| Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies Loncastuximab Tesirine, Bone Marrow Biopsy, Bone Marrow Aspiration - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | University of Washington | 11 | 2023-08-07 | 2026-06-15 |
| Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma Maplirpacept, Tafasitamab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Pfizer | 6 | 2023-08-04 | 2025-09-05 |
| A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug) - Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) | Phase 2 | Terminated | CARGO Therapeutics | 101 | 2023-08-01 | 2025-05-15 |
| Ritlecitinib in CTCL Ritlecitinib - CTCL, Mycosis Fungoides | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 7 | 2023-05-17 | 2025-07-18 |
| A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies ONCT-808, Bridging Therapy - Relapsed/Refractory Aggressive B-Cell Malignancies | Phase 1 / Phase 2 | Terminated | Oncternal Therapeutics, Inc | 9 | 2023-05-09 | 2024-12-05 |
| Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis NX-13 250mg, NX-13 750mg, NX-13 Placebo - Ulcerative Colitis | Phase 2 | Terminated | AbbVie | 81 | 2023-04-24 | 2026-06-15 |
| Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL CB-103, Venetoclax - Leukemia, Lymphoblastic, Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 2 | 2023-04-06 | 2025-11-26 |
| Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001) GEN1160 - Renal Cell Carcinoma, Nasopharyngeal Carcinoma | Phase 1 / Phase 2 | Terminated | Genmab | 42 | 2023-03-15 | 2026-03-04 |
| A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma Tafasitamab, Lenalidomide - Mantle Cell Lymphoma, MCL | Phase 2 | Terminated | Memorial Sloan Kettering Cancer Center | 4 | 2023-03-14 | 2025-05-25 |
| Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma Epcoritamab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | Genmab | 111 | 2023-03-06 | 2026-10-23 |
Showing 20 of 875. Sign in to see all of them.
Multiple Myeloma (247) · Lymphoma (182) · Lymphoma, Non-Hodgkin (169) · Leukemia, Lymphocytic, Chronic, B-Cell (156) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (131) · Lymphoma, Large B-Cell, Diffuse (123) · Lymphoma, Follicular (112) · Leukemia (107) · Recurrence (92) · Lymphoma, Mantle-Cell (80) · Hodgkin Disease (78) · Leukemia, Myeloid, Acute (73) · Myelodysplastic Syndromes (71) · Burkitt Lymphoma (52) · Lymphoma, B-Cell, Marginal Zone (50)
Hemic and Lymphatic Diseases (869) · Immune System Diseases (865) · Immunoproliferative Disorders (856) · Neoplasms by Histologic Type (851) · Neoplasms (820) · Lymphatic Diseases (667) · Hematologic Diseases (530) · Lymphoma (315) · Cardiovascular Diseases (286) · Vascular Diseases (285) · Paraproteinemias (282) · Blood Protein Disorders (280) · Hemorrhagic Disorders (280) · Hemostatic Disorders (278)
Rituximab (146) · Cyclophosphamide (104) · Dexamethasone (101) · Bortezomib (70) · Lenalidomide (60) · Calcium Dobesilate (51) · fludarabine (48) · Methotrexate (46) · Melphalan (41) · Vincristine (41) · fludarabine phosphate (40) · Doxorubicin (36) · Filgrastim (36) · Cytarabine (35) · Etoposide (35)
M.D. Anderson Cancer Center (54) · National Cancer Institute (NCI) (46) · Masonic Cancer Center, University of Minnesota (16) · Gilead Sciences (15) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (12) · Novartis Pharmaceuticals (11) · University of Washington (11) · Fred Hutchinson Cancer Center (10) · Mayo Clinic (10) · Weill Medical College of Cornell University (10) · Dana-Farber Cancer Institute (9) · H. Lee Moffitt Cancer Center and Research Institute (9) · Hoffmann-La Roche (9) · Northwestern University (9) · Washington University School of Medicine (9)
United States (685) · France (77) · Italy (77) · Spain (64) · Germany (59) · United Kingdom (49) · Canada (47) · Australia (42) · Belgium (36) · Poland (27) · South Korea (26) · Czechia (23) · Netherlands (23) · China (22) · Denmark (16)
Elias Jabbour (5) · James R Berenson, MD (4) · Stanislaw R. Burzynski, MD, PhD (4) · Ajay Gopal (3) · Amitabha Mazumder, MD (3)
PMID 35622074, PMID 41671463, PMID 26472751, PMID 31527168, PMID 34398557, PMID 35226739, PMID 39077906, PMID 11255275, PMID 11441933, PMID 12011122, PMID 12011123, PMID 12149300, PMID 12652460, PMID 16229966, PMID 17032388, PMID 17488673, PMID 17579184, PMID 18645136, PMID 18725106, PMID 19118065, PMID 19139736, PMID 19179301, PMID 19826119, PMID 20067838, PMID 20307284, PMID 21073974, PMID 21289631, PMID 21325353, PMID 21403127, PMID 21504290, PMID 21874061, PMID 22033282, PMID 22080968, PMID 22289993, PMID 22430088, PMID 22656234, PMID 22766223, PMID 23205612, PMID 23233571, PMID 23265768, PMID 23426279, PMID 23426943, PMID 23731832, PMID 23782682, PMID 23949430, PMID 24241210, PMID 24355079, PMID 24606326, PMID 24615776, PMID 24615777
2018 (17), 2016 (11), P30CA015704 (11), 2015 (9), 2023 (9), P30CA015083 (8), P30CA016672 (7), U10CA021115 (7), 2009 (5), 2017 (5), 2008 (4), 2014 (4), 2019 (4), U10CA032102 (4), N01CM17003 (3)